Advice
Following a full submission
Anagrelide (Xagrid) is not recommended for use within NHS Scotland for the reduction of elevated platelet counts in ‘at risk’ patients with essential thrombocythaemia who are intolerant of their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. The cost effectiveness of anagrelide has not been demonstrated.
The licence holder has indicated their decision to resubmit
Download detailed advice48KB (PDF)
Medicine details
- Medicine name:
- Anagrelide 0.5mg capsule (Xagrid®)
- SMC ID:
- 163/05
- Indication:
- Reduction of elevated platelet counts in 'at risk' patients with essential thrombocythaemia
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 May 2005